Cytiva opening new facility in Switzerland
share
Excerpt
Global life sciences leader Cytiva is opening a new 7400m² manufacturing facility in Grens, Switzerland on May 31, 2022.
Article Summary
Cytiva is opening its latest facility in Grens, Switzerland with over 7400m² in manufacturing area. The site will manufacture consumables for Xuri cell expansion systems and single use kits for the Sepax and Sefia cell processing systems. Besides, it will also serve as a ‘Center of Excellence’ for Cytiva’s Cell and Gene Therapy business and will be a base for European customer training programs.
The facility quadruples Cytiva’s capacity for manufacturing Sefia, Sepax, and Xuri consumable products with two new ISO class 7 cleanrooms, ensuring that increased future demand can be met. The design of the facility adopts GMP principles from raw materials entering the building, through the manufacturing process, to the shipment of finished products.
“Cell and gene therapies have the potential to change the global healthcare landscape. Our new facility in Grens will enable us to meet global demand for our products, while working with our customers to meet their immediate training and development needs. This facility brings us another step closer to our vision where access to life-changing therapies transforms human health,” Catarina Flyborg, Vice President, Cell and Gene Therapy, Cytiva said.
Philippe Leuba, Minister of Economic Affairs, Innovation and Sport, State of Vaud, Switzerland, says: “Cytiva is one of the world’s leading life sciences companies. Its decision to expand operations in Switzerland is a testament to our innovation ecosystem that has played a significant role in developing some of the most advanced therapeutics.”
About Cytiva
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in more than 40 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
Comments
Leave A Comment
Leave a Reply
